<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03285113</url>
  </required_header>
  <id_info>
    <org_study_id>CTC1601</org_study_id>
    <nct_id>NCT03285113</nct_id>
  </id_info>
  <brief_title>A Study to Confirm the Safety of High Frequency DRG Stimulator in Patients With Chronic Lower Limb Pain</brief_title>
  <official_title>A Single-arm, Open Label, Single Center Pilot Study to Confirm the Safety of Dorsal Root Ganglia (DRG) and Ultrahigh Frequency Spinal Cord Stimulator in Patients With Chronic Lower Limb Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GiMer Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GiMer Medical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, single-arm, open label, single center pilot study to confirm the&#xD;
      safety of a ultrahigh frequency DRG stimulator in patients with chronic lower limb pain. The&#xD;
      actual trial length is 5 days. Pts will be given ultrahigh frequency pulse stimulation, and&#xD;
      VAS will be obtained after 3-4 hours of each stimulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-arm, open label, single center pilot study to confirm the&#xD;
      safety of a ultrahigh frequency DRG stimulator in patients with chronic lower limb pain. The&#xD;
      actual trial length is 5 days. An initial eligibility screening within Day -14. Pt admitted&#xD;
      to hospital on Day 1. The lead implantation is conducted on Day 2, and the 1st treatment&#xD;
      starts after anesthesia recovery (Day 2 T1). If VAS &gt;4 at 4 hours after the 1st treatment,&#xD;
      the 2nd treatment will be conducted. VAS will be acquired 4 hours after the 2nd treatment. On&#xD;
      Day 3, physical examination and vital signs will be collected. If VAS &gt;4, the 3rd treatment&#xD;
      will be provided. One hour after the 3rd treatment, the device will be removed and an X-ray&#xD;
      will be taken. Three hours after the removal, VAS will be collected and then the patient will&#xD;
      be discharged. VAS will be estimated by phone call on Day 4, and the patient will return to&#xD;
      OPD for follow up examination on Day 5. The trial is completed on Day 5 visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Actual">February 5, 2018</completion_date>
  <primary_completion_date type="Actual">February 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Ultrahigh Frequency Treatment: Adverse Event (AE) and Serious AE (SAE)</measure>
    <time_frame>5 days</time_frame>
    <description>Number of Participants with Adverse Events and Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Measured by Visual Analog Scale (VAS)</measure>
    <time_frame>4 days</time_frame>
    <description>VAS: 0 (no pain) to 10 (max pain). Change in pain as a result of ultrahigh frequency DRG stimulation, as measured by VAS score compare to baseline VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Paresthesia</measure>
    <time_frame>2 days</time_frame>
    <description>If patients feel tingling during stimulation?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Medication Consumption</measure>
    <time_frame>5 days</time_frame>
    <description>Decrease in pain medication consumption, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and weak opioids, compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Failed Back Surgery Syndrome</condition>
  <condition>Complex Regional Pain Syndrome (CRPS)</condition>
  <arm_group>
    <arm_group_label>Ultrahigh Frequency Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GiMer Medical MN 1000 External Stimulator</intervention_name>
    <description>Trial stimulator to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
    <arm_group_label>Ultrahigh Frequency Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≧20 and ≦75&#xD;
&#xD;
          2. Have a symptom of complex regional pain syndrome (CRPS), failed back surgery syndrome&#xD;
             (FBSS), lower limb pain with or without lower back pain with a diagnosis related to&#xD;
             spinal lesion and pain history of &gt;6 months.&#xD;
&#xD;
          3. Have an average pain score &gt;5 by Visual Analogue Scale (VAS) on inclusion.&#xD;
&#xD;
          4. Has failed to achieve adequate pain relief from prior pharmacologic treatments.&#xD;
&#xD;
          5. In the judgement of the investigator, the subject is an appropriate candidate for the&#xD;
             trial procedure&#xD;
&#xD;
          6. The subject is willing and able to comply with the procedure and requirements of this&#xD;
             trial.&#xD;
&#xD;
          7. The participant is able to understand and provide informed consent, and has signed&#xD;
             their written informed consent in accordance with IRB requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have evidence of a mental or psychological condition that affects pain perception and&#xD;
             has difficulty/disability performing objective pain assessment, or have previously&#xD;
             failed mental or psychological assessments administered by a psychiatrist that may be&#xD;
             deemed to indicate the subject's lack of suitability for participation in this study.&#xD;
&#xD;
          2. Subject has exhibited escalating or changing pain condition within the past 30 days as&#xD;
             evidenced by Investigator examination.&#xD;
&#xD;
          3. Be on anticoagulant medication with INR &gt;1.5 or platelet count less than 100,000/μL,&#xD;
             peripheral vascular diseases (PVDs), visceral pain or uncontrolled Diabetes mellitus&#xD;
             (DM).&#xD;
&#xD;
          4. Has had corticosteroid therapy at an intended site of stimulation within the past 30&#xD;
             days.&#xD;
&#xD;
          5. Pain medication(s) dosages(s) are not stable for at least 30 days.&#xD;
&#xD;
          6. Has previously failed spinal cord stimulation therapy.&#xD;
&#xD;
          7. Currently has an active implantable device including ICD, pacemaker, spinal cord&#xD;
             stimulator or intrathecal drug pump or subject requires magnetic resonance imaging&#xD;
             (MRIs) or diathermy.&#xD;
&#xD;
          8. Has pain only within a cervical or thoracic distribution.&#xD;
&#xD;
          9. Have a current diagnosis of cancer with active symptoms&#xD;
&#xD;
         10. Have a known terminal illness with life expectancy less than one year&#xD;
&#xD;
         11. Have a systematic or local infection&#xD;
&#xD;
         12. Currently has an indwelling device that may pose an increased risk of infection.&#xD;
&#xD;
         13. Be pregnant or breast feeding&#xD;
&#xD;
         14. Have a medical history of drug or alcohol addiction within the past 2 years.&#xD;
&#xD;
         15. Participation in any investigational study in the last 30 days or current enrollment&#xD;
             in any trial.&#xD;
&#xD;
         16. Be currently involved in an injury claim law suit or medically related litigation,&#xD;
             including workers compensation.&#xD;
&#xD;
         17. Be a prisoner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <results_first_submitted>June 5, 2020</results_first_submitted>
  <results_first_submitted_qc>December 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Failed Back Surgery Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03285113/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ultrahigh Frequency Stimulation</title>
          <description>Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unable to implant leads</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ultrahigh Frequency Stimulation</title>
          <description>Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of Ultrahigh Frequency Treatment: Adverse Event (AE) and Serious AE (SAE)</title>
        <description>Number of Participants with Adverse Events and Serious Adverse Events</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrahigh Frequency Stimulation</title>
            <description>Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Ultrahigh Frequency Treatment: Adverse Event (AE) and Serious AE (SAE)</title>
          <description>Number of Participants with Adverse Events and Serious Adverse Events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Measured by Visual Analog Scale (VAS)</title>
        <description>VAS: 0 (no pain) to 10 (max pain). Change in pain as a result of ultrahigh frequency DRG stimulation, as measured by VAS score compare to baseline VAS.</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrahigh Frequency Stimulation</title>
            <description>Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Measured by Visual Analog Scale (VAS)</title>
          <description>VAS: 0 (no pain) to 10 (max pain). Change in pain as a result of ultrahigh frequency DRG stimulation, as measured by VAS score compare to baseline VAS.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Paresthesia</title>
        <description>If patients feel tingling during stimulation?</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrahigh Frequency Stimulation</title>
            <description>Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Paresthesia</title>
          <description>If patients feel tingling during stimulation?</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Medication Consumption</title>
        <description>Decrease in pain medication consumption, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and weak opioids, compared to baseline</description>
        <time_frame>5 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ultrahigh Frequency Stimulation</title>
            <description>Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Medication Consumption</title>
          <description>Decrease in pain medication consumption, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and weak opioids, compared to baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Trial duration (4 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ultrahigh Frequency Stimulation</title>
          <description>Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.&#xD;
GiMer Medical MN 1000 External Stimulator: Trial stimulator to generate pulsed ultrahigh frequency (&gt;200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>procedural headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increase blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yeong-Ray Wen (Department of Anaesthesia)</name_or_title>
      <organization>China Medical University Hospital (in Taiwan)</organization>
      <phone>+886 4 2205-2121</phone>
      <email>yray.wen@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

